• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
The Role of PPARgamma in pulmonary vascular disease.过氧化物酶体增殖物激活受体γ在肺血管疾病中的作用。
J Investig Med. 2008 Feb;56(2):518-21. doi: 10.2310/JIM.0b013e318165e921.
2
Redox Biology of Peroxisome Proliferator-Activated Receptor-γ in Pulmonary Hypertension.过氧化物酶体增殖物激活受体-γ 在肺动脉高压中的氧化还原生物学。
Antioxid Redox Signal. 2019 Oct 20;31(12):874-897. doi: 10.1089/ars.2018.7695. Epub 2019 Feb 25.
3
PPARgamma as a potential therapeutic target in pulmonary hypertension.过氧化物酶体增殖物激活受体γ 作为肺动脉高压的潜在治疗靶点。
Ther Adv Respir Dis. 2010 Jun;4(3):143-60. doi: 10.1177/1753465809369619.
4
Hypoxia downregulates PPARγ via an ERK1/2-NF-κB-Nox4-dependent mechanism in human pulmonary artery smooth muscle cells.缺氧通过 ERK1/2-NF-κB-Nox4 依赖性机制下调人肺动脉平滑肌细胞中的 PPARγ。
Free Radic Biol Med. 2013 Oct;63:151-60. doi: 10.1016/j.freeradbiomed.2013.05.013. Epub 2013 May 15.
5
PPARgamma and the pathobiology of pulmonary arterial hypertension.过氧化物酶体增殖物激活受体γ与肺动脉高压的病理生物学。
Adv Exp Med Biol. 2010;661:447-58. doi: 10.1007/978-1-60761-500-2_29.
6
Peroxisome Proliferator-Activated Receptor γ Regulates the V-Ets Avian Erythroblastosis Virus E26 Oncogene Homolog 1/microRNA-27a Axis to Reduce Endothelin-1 and Endothelial Dysfunction in the Sickle Cell Mouse Lung.过氧化物酶体增殖物激活受体γ调节V-Ets禽成红细胞增多症病毒E26癌基因同源物1/微小RNA-27a轴，以减轻镰状细胞小鼠肺中的内皮素-1和内皮功能障碍。
Am J Respir Cell Mol Biol. 2017 Jan;56(1):131-144. doi: 10.1165/rcmb.2016-0166OC.
7
Peroxisome proliferator-activated receptor gamma (PPARgamma) and immunoregulation: enhancement of regulatory T cells through PPARgamma-dependent and -independent mechanisms.过氧化物酶体增殖物激活受体γ（PPARγ）与免疫调节：通过PPARγ依赖性和非依赖性机制增强调节性T细胞
J Immunol. 2007 Apr 1;178(7):4129-35. doi: 10.4049/jimmunol.178.7.4129.
8
PPARγ is a gatekeeper for extracellular matrix and vascular cell homeostasis: beneficial role in pulmonary hypertension and renal/cardiac/pulmonary fibrosis.过氧化物酶体增殖物激活受体γ（PPARγ）是细胞外基质和血管细胞稳态的守门员：在肺动脉高压以及肾/心/肺纤维化中发挥有益作用。
Curr Opin Nephrol Hypertens. 2020 Mar;29(2):171-179. doi: 10.1097/MNH.0000000000000580.
9
Peroxisome proliferator-activated receptor-γ ameliorates pulmonary arterial hypertension by inhibiting 5-hydroxytryptamine 2B receptor.过氧化物酶体增殖物激活受体-γ 通过抑制 5-羟色胺 2B 受体减轻肺动脉高压。
Hypertension. 2012 Dec;60(6):1471-8. doi: 10.1161/HYPERTENSIONAHA.112.198887. Epub 2012 Oct 29.
10
Peroxisome proliferator-activated receptor gamma as a novel therapeutic target in asthma.过氧化物酶体增殖物激活受体γ作为哮喘的新型治疗靶点
J Asthma. 2008 Jan-Feb;45(1):1-8. doi: 10.1080/02770900701247319.

引用本文的文献

1
Idiopathic pulmonary fibrosis and pulmonary hypertension: Heracles meets the Hydra.特发性肺纤维化与肺动脉高压：赫拉克勒斯遭遇九头蛇。
Br J Pharmacol. 2021 Jan;178(1):172-186. doi: 10.1111/bph.15036. Epub 2020 Apr 7.
2
Pulmonary vascular dysfunction in metabolic syndrome.代谢综合征中的肺血管功能障碍。
J Physiol. 2019 Feb;597(4):1121-1141. doi: 10.1113/JP275856. Epub 2018 Sep 12.
3
Repurposing rosiglitazone, a PPAR-γ agonist and oral antidiabetic, as an inhaled formulation, for the treatment of PAH.将吡格列酮（一种过氧化物酶体增殖物激活受体γ激动剂和口服抗糖尿病药物）重新用于治疗肺动脉高压的吸入制剂。
J Control Release. 2018 Jun 28;280:113-123. doi: 10.1016/j.jconrel.2018.04.049. Epub 2018 Apr 30.
4
Impact of diabetes in patients with pulmonary hypertension.糖尿病对肺动脉高压患者的影响。
Pulm Circ. 2015 Mar;5(1):117-23. doi: 10.1086/679705.
5
PPAR-γ regulates carnitine homeostasis and mitochondrial function in a lamb model of increased pulmonary blood flow.过氧化物酶体增殖物激活受体-γ 在增加肺血流量的羔羊模型中调节肉碱稳态和线粒体功能。
PLoS One. 2012;7(9):e41555. doi: 10.1371/journal.pone.0041555. Epub 2012 Sep 4.
6
Novel strategy for treatment of pulmonary arterial hypertension: enhancement of apoptosis.肺动脉高压治疗的新策略：促进细胞凋亡。
Lung. 2010 Jun;188(3):179-89. doi: 10.1007/s00408-010-9233-8. Epub 2010 Mar 6.
7
The PPARbeta/delta agonist GW0742 relaxes pulmonary vessels and limits right heart hypertrophy in rats with hypoxia-induced pulmonary hypertension.PPARβ/δ激动剂 GW0742 可舒张低氧性肺动脉高压大鼠的肺血管并限制右心肥厚。
PLoS One. 2010 Mar 4;5(3):e9526. doi: 10.1371/journal.pone.0009526.
8
Molecular aspects of thyroid hormone actions.甲状腺激素作用的分子方面。
Endocr Rev. 2010 Apr;31(2):139-70. doi: 10.1210/er.2009-0007. Epub 2010 Jan 5.

本文引用的文献

1
Rosiglitazone attenuates chronic hypoxia-induced pulmonary hypertension in a mouse model.罗格列酮可减轻小鼠慢性低氧性肺动脉高压。
Am J Respir Cell Mol Biol. 2010 Apr;42(4):482-90. doi: 10.1165/rcmb.2008-0132OC. Epub 2009 Jun 11.
2
Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferator-activated receptor-gamma activation.肺动脉高压与胰岛素抵抗相关，而过氧化物酶体增殖物激活受体γ激活可逆转这种关系。
Circulation. 2007 Mar 13;115(10):1275-84. doi: 10.1161/CIRCULATIONAHA.106.663120. Epub 2007 Mar 5.
3
The PPARgamma ligand, rosiglitazone, reduces vascular oxidative stress and NADPH oxidase expression in diabetic mice.过氧化物酶体增殖物激活受体γ（PPARγ）配体罗格列酮可降低糖尿病小鼠的血管氧化应激及NADPH氧化酶表达。
Vascul Pharmacol. 2007 Jun;46(6):456-62. doi: 10.1016/j.vph.2007.01.007. Epub 2007 Feb 8.
4
Rosiglitazone attenuates hypoxia-induced pulmonary arterial remodeling.罗格列酮可减轻缺氧诱导的肺动脉重塑。
Am J Physiol Lung Cell Mol Physiol. 2007 Apr;292(4):L885-97. doi: 10.1152/ajplung.00258.2006. Epub 2006 Dec 22.
5
Peroxisome proliferator-activated receptor-gamma activation with pioglitazone improves endothelium-dependent dilation in nondiabetic patients with major cardiovascular risk factors.吡格列酮激活过氧化物酶体增殖物激活受体γ可改善伴有主要心血管危险因素的非糖尿病患者的内皮依赖性血管舒张功能。
Circulation. 2006 Feb 14;113(6):867-75. doi: 10.1161/CIRCULATIONAHA.105.549618. Epub 2006 Feb 6.
6
Chronic ethanol exposure stimulates endothelial cell nitric oxide production through PI-3 kinase-and hsp90-dependent mechanisms.长期乙醇暴露通过PI-3激酶和热休克蛋白90依赖性机制刺激内皮细胞一氧化氮生成。
Alcohol Clin Exp Res. 2005 Nov;29(11):1932-8. doi: 10.1097/01.alc.0000187597.62590.a4.
7
Pulmonary hypertension surveillance--United States, 1980-2002.1980 - 2002年美国肺动脉高压监测
MMWR Surveill Summ. 2005 Nov 11;54(5):1-28.
8
Peroxisome proliferator-activated receptor gamma ligands stimulate endothelial nitric oxide production through distinct peroxisome proliferator-activated receptor gamma-dependent mechanisms.过氧化物酶体增殖物激活受体γ配体通过不同的过氧化物酶体增殖物激活受体γ依赖性机制刺激内皮细胞一氧化氮生成。
Arterioscler Thromb Vasc Biol. 2005 Sep;25(9):1810-6. doi: 10.1161/01.ATV.0000177805.65864.d4. Epub 2005 Jul 14.
9
[Effects of peroxisome proliferator-activated receptor gamma ligands on monocrotaline-induced pulmonary hypertension in rats].过氧化物酶体增殖物激活受体γ配体对野百合碱诱导的大鼠肺动脉高压的影响
Nihon Kokyuki Gakkai Zasshi. 2005 May;43(5):283-8.
10
Peroxisome proliferator-activated receptor-gamma ligands regulate endothelial membrane superoxide production.过氧化物酶体增殖物激活受体γ配体调节内皮细胞膜超氧化物的产生。
Am J Physiol Cell Physiol. 2005 Apr;288(4):C899-905. doi: 10.1152/ajpcell.00474.2004. Epub 2004 Dec 8.

过氧化物酶体增殖物激活受体γ在肺血管疾病中的作用。

The Role of PPARgamma in pulmonary vascular disease.

作者信息

Hart C Michael

机构信息

Atlanta Veterans Affairs Medical Center, Atlanta, GA, USA.

出版信息

J Investig Med. 2008 Feb;56(2):518-21. doi: 10.2310/JIM.0b013e318165e921.

DOI:10.2310/JIM.0b013e318165e921
PMID:18317434
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4484596/
Abstract

The peroxisome proliferator-activated receptor (PPAR) gamma is a member of the nuclear hormone receptor superfamily of ligand-activated transcription factors. Thiazolidinediones, pharmacological ligands for PPARgamma, are currently used in the management of type 2 diabetes. Peroxisome proliferator-activated receptor gamma is expressed in the lung and pulmonary vasculature, and its expression is reduced in the vascular lesions of patients with pulmonary hypertension. Furthermore, thiazolidinedione PPARgamma ligands reduced pulmonary hypertension and vascular remodeling in several experimental models of pulmonary hypertension. This report reviews current evidence that PPARgamma may represent a novel therapeutic target in pulmonary hypertension and examines studies that have begun to elucidate mechanisms that underlie these potential therapeutic effects.

摘要

过氧化物酶体增殖物激活受体（PPAR）γ是配体激活转录因子核激素受体超家族的成员。噻唑烷二酮类药物是PPARγ的药理学配体，目前用于2型糖尿病的治疗。过氧化物酶体增殖物激活受体γ在肺和肺血管系统中表达，在肺动脉高压患者的血管病变中其表达降低。此外，噻唑烷二酮类PPARγ配体在几种肺动脉高压实验模型中降低了肺动脉高压和血管重塑。本报告综述了目前关于PPARγ可能是肺动脉高压新治疗靶点的证据，并审视了已开始阐明这些潜在治疗作用机制的研究。